

# Stefano Indraccolo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4698798/publications.pdf>

Version: 2024-02-01

186  
papers

7,386  
citations

53751

45  
h-index

69214

77  
g-index

189  
all docs

189  
docs citations

189  
times ranked

12877  
citing authors

#	ARTICLE	IF	CITATIONS
1	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. <i>Oncologist</i> , 2022, 27, 87-e115.	1.9	25
2	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. <i>British Journal of Cancer</i> , 2022, 127, 383-393.	2.9	36
3	mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells. <i>Redox Biology</i> , 2022, 51, 102268.	3.9	14
4	SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 377-388.	3.3	68
5	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. <i>Neuro-Oncology</i> , 2021, 23, 264-276.	0.6	48
6	Filling the gap between risk assessment and molecular determinants of tumor onset. <i>Carcinogenesis</i> , 2021, 42, 507-516.	1.3	3
7	Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia. <i>Theranostics</i> , 2021, 11, 1594-1608.	4.6	3
8	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. <i>Translational Lung Cancer Research</i> , 2021, 10, 202-220.	1.3	29
9	Genetic Perturbation of Pyruvate Dehydrogenase Kinase 1 Modulates Growth, Angiogenesis and Metabolic Pathways in Ovarian Cancer Xenografts. <i>Cells</i> , 2021, 10, 325.	1.8	9
10	ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 625636.	1.3	8
11	Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 363.	1.3	7
12	A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. <i>Blood</i> , 2021, 138, 1317-1330.	0.6	11
13	Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures. <i>Nature Communications</i> , 2021, 12, 2507.	5.8	22
14	BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer. <i>British Journal of Pharmacology</i> , 2021, 178, 3627-3647.	2.7	13
15	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103378.	2.0	12
16	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021, 17, 2513-2527.	1.1	7
17	Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Diagnostics</i> , 2021, 11, 1468.	1.3	7
18	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020, 21, 1-14.e3.	1.1	19

#	ARTICLE	IF	CITATIONS
19	Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 66.	1.8	12
20	A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Diagnostics</i> , 2020, 10, 765.	1.3	7
21	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. <i>ESMO Open</i> , 2020, 5, e000748.	2.0	2
22	In situ Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology Approach. <i>Frontiers in Oncology</i> , 2020, 10, 1277.	1.3	8
23	Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. <i>Cancers</i> , 2020, 12, 2283.	1.7	41
24	Genetic perturbation of IFN- $\gamma$ transcriptional modulators in human endothelial cells uncovers pivotal regulators of angiogenesis. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 3977-3986.	1.9	6
25	Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020, 123, 81-91.	2.9	35
26	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4478-4484.	3.2	20
27	Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. <i>Oncologist</i> , 2020, 25, e1996-e2005.	1.9	21
28	Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1601.	1.8	7
29	Metabolism in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1263, 1-11.	0.8	11
30	Comparison of the Genomic Profile of Cancer Stem Cells and Their Non-Stem Counterpart: The Case of Ovarian Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 368.	1.0	10
31	Evolving use of liquid biopsy in non-small-cell-lung cancer patients. <i>International Journal of Biological Markers</i> , 2020, 35, 23-25.	0.7	3
32	Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts. <i>Haematologica</i> , 2020, 105, 1317-1328.	1.7	9
33	Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 607840.	1.3	10
34	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. <i>Cancer Treatment Reviews</i> , 2020, 87, 102031.	3.4	82
35	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
36	Editorial on "The AvaALL Randomized Clinical Trial". <i>Journal of Thoracic Disease</i> , 2019, 11, S1237-S1240.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983954.	1.4	35
38	Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 821.	1.1	22
39	Crizotinib in <i>MET</i> -Deregulated or <i>ROS1</i> -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7312-7319.	3.2	139
40	PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 128-134.	2.0	66
41	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1874.	1.8	39
42	LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-16.	1.9	78
43	18F-FDG PET/CT in non-small-cell lung cancer patients. <i>Nuclear Medicine Communications</i> , 2019, 40, 802-807.	0.5	63
44	Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy. <i>Cells</i> , 2019, 8, 1601.	1.8	25
45	Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2019, 70, 700-709.	1.8	112
46	Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 1828-1837.	3.2	72
47	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 110-119.	5.1	238
48	Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients (PTS) with mismatch repair deficiency (MMRd): An observational study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2043-2043.	0.8	2
49	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for <i>EGFR</i> -Positive Non-Small Cell Lung Cancer (MOST Study). <i>Oncologist</i> , 2019, 24, e318-e326.	1.9	5
50	Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases. <i>Translational Lung Cancer Research</i> , 2019, 8, S435-S438.	1.3	2
51	Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC. <i>Journal of Clinical Oncology</i> , 2019, 37, e20612-e20612.	0.8	0
52	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876374.	1.4	30
53	Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells. <i>Oncogene</i> , 2018, 37, 3839-3851.	2.6	26
54	LKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and $^{137}\text{Cs}$ -irradiation. <i>Biochemical Pharmacology</i> , 2018, 156, 479-490.	2.0	30

#	ARTICLE	IF	CITATIONS
55	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1692-1704.	0.5	74
56	Precision medicine in cholangiocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 40-40.	1.5	61
57	Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1021-1030.	1.1	21
58	Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis. <i>Cell Death and Disease</i> , 2018, 9, 822.	2.7	23
59	Involvement of NADPH Oxidase 1 in Liver Kinase B1-Mediated Effects on Tumor Angiogenesis and Growth. <i>Frontiers in Oncology</i> , 2018, 8, 195.	1.3	10
60	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2047-2047.	0.8	4
61	Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24074-e24074.	0.8	0
62	Abstract 2406: Metabolic phenotype and metastasis in patient-derived ovarian cancer xenografts. , 2018, , .		0
63	The Nucleotide Kinase Ndk Is Required for ROS Detoxification and Constitutes a Metabolic Vulnerability of NOTCH1-Driven T-ALL. <i>Blood</i> , 2018, 132, 2615-2615.	0.6	1
64	Linking metabolic reprogramming to therapy resistance in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 1-6.	3.3	117
65	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-“Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. <i>Clinical Cancer Research</i> , 2017, 23, 3316-3324.	3.2	43
66	Absence of Neurofibromin Induces an Oncogenic Metabolic Switch via Mitochondrial ERK-Mediated Phosphorylation of the Chaperone TRAP1. <i>Cell Reports</i> , 2017, 18, 659-672.	2.9	81
67	Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors. <i>Scientific Reports</i> , 2017, 7, 13936.	1.6	45
68	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 30-39.	2.0	40
69	Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by different growth factors. <i>British Journal of Pharmacology</i> , 2017, 174, 3094-3106.	2.7	46
70	Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2017, 130, 2750-2761.	0.6	54
71	Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells. <i>Oncotarget</i> , 2017, 8, 6433-6445.	0.8	29
72	REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2085-TPS2085.	0.8	3

#	ARTICLE	IF	CITATIONS
73	ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 26129-26141.	0.8	21
74	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , 2017, 8, 32626-32638.	0.8	14
75	Modulation of the anti-tumor activity of VEGF blockade by metformin.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23009-e23009.	0.8	0
76	Next generation sequencing in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD)., 2017, , .		0
77	Potential of Induced Metabolic Bioluminescence Imaging to Uncover Metabolic Effects of Antiangiogenic Therapy in Tumors. <i>Frontiers in Oncology</i> , 2016, 6, 15.	1.3	5
78	In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 164.	1.3	8
79	An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. <i>Cell Death and Disease</i> , 2016, 7, e2047-e2047.	2.7	15
80	166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series. <i>Journal of Thoracic Oncology</i> , 2016, 11, S130.	0.5	0
81	28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS). <i>Journal of Thoracic Oncology</i> , 2016, 11, S67.	0.5	0
82	77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC). <i>Journal of Thoracic Oncology</i> , 2016, 11, S88.	0.5	1
83	Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. <i>Cell Reports</i> , 2016, 15, 1134-1143.	2.9	96
84	Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. <i>Journal of Leukocyte Biology</i> , 2016, 99, 1077-1087.	1.5	41
85	Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. <i>Cancer Research</i> , 2016, 76, 4775-4784.	0.4	44
86	Reconstruction of gene regulatory modules from RNA silencing of IFN- $\lambda$ modulators: experimental set-up and inference method. <i>BMC Genomics</i> , 2016, 17, 228.	1.2	3
87	Vascular endothelial growth factor blockade elicits a stable metabolic shift in tumor cells: therapeutic implications. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1008307.	0.3	2
88	Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein degradation. <i>Leukemia</i> , 2016, 30, 812-822.	3.3	15
89	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. <i>Lung Cancer</i> , 2016, 96, 52-55.	0.9	8
90	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. <i>Oncotarget</i> , 2016, 7, 72654-72661.	0.8	15

#	ARTICLE	IF	CITATIONS
91	A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model. <i>Oncotarget</i> , 2016, 7, 33081-33095.	0.8	15
92	Uncovering Metabolic Effects of Anti-angiogenic Therapy in Tumors by Induced Metabolic Bioluminescence Imaging. <i>Methods in Molecular Biology</i> , 2016, 1464, 175-184.	0.4	2
93	Pharmacological Inhibition of Lck is Able to Revert Glucocorticoid Resistance in Pediatric T-ALL. <i>Blood</i> , 2016, 128, 838-838.	0.6	0
94	EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. <i>BMC Cancer</i> , 2015, 15, 855.	1.1	13
95	Metformin: a modulator of bevacizumab activity in cancer? A case report. <i>Cancer Biology and Therapy</i> , 2015, 16, 210-214.	1.5	13
96	Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. <i>Cell Death and Disease</i> , 2015, 6, e1774-e1774.	2.7	28
97	Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model system. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 377-385.	2.1	11
98	VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells. <i>Cancer Research</i> , 2015, 75, 120-133.	0.4	62
99	DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice. <i>Carcinogenesis</i> , 2015, 36, 115-121.	1.3	33
100	Abstract 1182: Metformin affects breast cancer cell growth and disturbs an IGF1/insulin related gene network that correlates with breast cancer progression. <i>Cancer Research</i> , 2015, 75, 1182-1182.	0.4	0
101	Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. <i>Oncotarget</i> , 2014, 5, 4305-4319.	0.8	249
102	Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. <i>Leukemia</i> , 2014, 28, 278-288.	3.3	108
103	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. <i>British Journal of Cancer</i> , 2014, 111, 25-32.	2.9	41
104	Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4647-4659.	3.2	130
105	Notch and NF- $\kappa$ B signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 2324-2335.	3.3	147
106	NOTCH3 Signaling Regulates MUSASHI-1 Expression in Metastatic Colorectal Cancer Cells. <i>Cancer Research</i> , 2014, 74, 2106-2118.	0.4	56
107	Metabolic effects of antiangiogenic drugs in tumors: Therapeutic implications. <i>Biochemical Pharmacology</i> , 2014, 89, 162-170.	2.0	20
108	Wnt activation promotes neuronal differentiation of Glioblastoma. <i>Cell Death and Disease</i> , 2013, 4, e500-e500.	2.7	89

#	ARTICLE	IF	CITATIONS
109	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2013, 24, 766-776.	7.7	220
110	hTERT Inhibition Triggers Epstein-Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies. <i>Clinical Cancer Research</i> , 2013, 19, 2036-2047.	3.2	27
111	Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. <i>Hepatology</i> , 2013, 58, 1042-1053.	3.6	139
112	Insights into the Regulation of Tumor Dormancy by Angiogenesis in Experimental Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2013, 734, 37-52.	0.8	18
113	ZNF521 Is a Zinc Finger Protein That Prevents Differentiation Of Human MLL-AF9-Positive Myeloid Leukemic Cells. <i>Blood</i> , 2013, 122, 1255-1255.	0.6	0
114	BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1 $\alpha$ stability and MGMT expression. <i>Cell Death and Disease</i> , 2012, 3, e412-e412.	2.7	132
115	Signaling Pathways in Cancer Stem Cells: Therapeutic Implications. , 2012, , 3-11.		0
116	Metabolic effects of anti-angiogenic therapy in tumors. <i>Biochimie</i> , 2012, 94, 925-931.	1.3	12
117	Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts. <i>FEBS Journal</i> , 2012, 279, 882-891.	2.2	33
118	Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. <i>Blood</i> , 2011, 117, 7053-7062.	0.6	199
119	Efficacy Assessment of Interferon-Alpha-Engineered Mesenchymal Stromal Cells in a Mouse Plasmacytoma Model. <i>Stem Cells and Development</i> , 2011, 20, 709-719.	1.1	19
120	Notch3 signalling promotes tumour growth in colorectal cancer. <i>Journal of Pathology</i> , 2011, 224, 448-460.	2.1	77
121	Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. <i>Hepatology</i> , 2011, 54, 890-899.	3.6	82
122	Vandetanib Improves Anti-Tumor Effects of L19mTNF $\alpha$ in Xenograft Models of Esophageal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 447-458.	3.2	20
123	Long Pentraxin-3 Inhibits FGF8b-Dependent Angiogenesis and Growth of Steroid Hormone-Regulated Tumors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1600-1610.	1.9	53
124	Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization. <i>Cancer Research</i> , 2011, 71, 4214-4225.	0.4	67
125	Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 419-439.	1.7	15
126	Ligand-driven activation of the Notch pathway in T-cell and solid tumors: Why Not(ch)? <i>Cell Cycle</i> , 2010, 9, 80-85.	1.3	16

#	ARTICLE	IF	CITATIONS
127	Side population and cancer stem cells: Therapeutic implications. <i>Cancer Letters</i> , 2010, 288, 1-9.	3.2	109
128	Interferon- $\beta$ as angiogenesis inhibitor: Learning from tumor models. <i>Autoimmunity</i> , 2010, 43, 244-247.	1.2	75
129	M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis. <i>Clinical Cancer Research</i> , 2010, 16, 5233-5243.	3.2	124
130	Cross-talk between Tumor and Endothelial Cells Involving the Notch3-Dll4 Interaction Marks Escape from Tumor Dormancy. <i>Cancer Research</i> , 2009, 69, 1314-1323.	0.4	124
131	The Angiogenic Switch: Implications in the Regulation of Tumor Dormancy. <i>Current Molecular Medicine</i> , 2009, 9, 935-941.	0.6	58
132	Interferon- $\beta$ counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. <i>Carcinogenesis</i> , 2009, 30, 851-860.	1.3	33
133	Impact of VEGF-dependent tumour microenvironment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. <i>Journal of Pathology</i> , 2009, 219, 455-462.	2.1	17
134	Hypoxia and HIF1 $\beta$ Repress the Differentiative Effects of BMPs in High-Grade Glioma. <i>Stem Cells</i> , 2009, 27, 7-17.	1.4	100
135	Antineoplastic activity of lentiviral vectors expressing interferon- $\beta$ in a preclinical model of primary effusion lymphoma. <i>Blood</i> , 2009, 113, 4525-4533.	0.6	18
136	Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy. <i>Apmis</i> , 2008, 116, 648-659.	0.9	52
137	Tumor-Targeted Interferon- $\beta$ Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis. <i>Cancer Cell</i> , 2008, 14, 299-311.	7.7	267
138	Hypoxia Inducible Factor-1 $\beta$ Inactivation Unveils a Link between Tumor Cell Metabolism and Hypoxia-Induced Cell Death. <i>American Journal of Pathology</i> , 2008, 173, 1186-1201.	1.9	39
139	The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN- $\beta$ Antitumor Effects. <i>Cancer Research</i> , 2008, 68, 5658-5668.	0.4	121
140	Identification of Genes Selectively Regulated by IFNs in Endothelial Cells. <i>Journal of Immunology</i> , 2007, 178, 1122-1135.	0.4	152
141	Differential Regulation of Hypoxia-Induced CXCR4 Triggering during B-Cell Development and Lymphomagenesis. <i>Cancer Research</i> , 2007, 67, 8605-8614.	0.4	41
142	Concluding remarks. <i>Molecular Aspects of Medicine</i> , 2007, 28, 167.	2.7	1
143	RNA interference: Implications for cancer treatment. <i>Molecular Aspects of Medicine</i> , 2007, 28, 143-166.	2.7	60
144	Anti-angiogenic gene therapy of cancer: Current status and future prospects. <i>Molecular Aspects of Medicine</i> , 2007, 28, 87-114.	2.7	62

#	ARTICLE	IF	CITATIONS
145	Angiogenesis meets immunology: Cytokine gene therapy of cancer. <i>Molecular Aspects of Medicine</i> , 2007, 28, 59-86.	2.7	18
146	Genes in the cure of cancer. <i>Molecular Aspects of Medicine</i> , 2007, 28, 1-3.	2.7	1
147	hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: Implications for EBV-driven lymphomagenesis. <i>International Journal of Cancer</i> , 2007, 121, 576-587.	2.3	33
148	Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 $\hat{\wedge}$ / $\hat{\wedge}$ epithelial ovarian cancers. <i>European Journal of Cancer</i> , 2006, 42, 1475-1483.	1.3	28
149	Gene therapy of ovarian cancer with IFN- $\hat{\pm}$ -producing fibroblasts: comparison of constitutive and inducible vectors. <i>Gene Therapy</i> , 2006, 13, 953-965.	2.3	19
150	Dormant Tumors Awaken by a Short-Term Angiogenic Burst: The Spike Hypothesis. <i>Cell Cycle</i> , 2006, 5, 1751-1755.	1.3	46
151	Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 4216-4221.	3.3	113
152	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. <i>Blood</i> , 2005, 105, 931-939.	0.6	38
153	Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. <i>British Journal of Haematology</i> , 2005, 130, 878-889.	1.2	11
154	Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: Microarray gene expression analyses. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005, 591, 198-211.	0.4	25
155	Interferon- $\hat{\pm}$ Gene Therapy by Lentiviral Vectors Contrasts Ovarian Cancer Growth Through Angiogenesis Inhibition. <i>Human Gene Therapy</i> , 2005, 16, 957-970.	1.4	34
156	Interferon- Gene Therapy by Lentiviral Vectors Contrasts Ovarian Cancer Growth Through Angiogenesis Inhibition. <i>Human Gene Therapy</i> , 2005, .	1.4	0
157	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. <i>Journal of Immunological Methods</i> , 2004, 291, 153-163.	0.6	6
158	Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells. <i>Experimental Cell Research</i> , 2004, 295, 539-548.	1.2	23
159	Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. <i>Blood</i> , 2004, 104, 92-99.	0.6	181
160	Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field. <i>Current Gene Therapy</i> , 2004, 4, 297-308.	0.9	23
161	Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. <i>Experimental Cell Research</i> , 2003, 287, 28-38.	1.2	24
162	Antiangiogenic Therapy Against Experimental Glioblastoma Using Genetically Engineered Cells Producing Interferon- $\hat{\pm}$ , Angiostatin, or Endostatin. <i>Human Gene Therapy</i> , 2003, 14, 883-895.	1.4	46

#	ARTICLE	IF	CITATIONS
163	Retroviral Vectors for High-Level Transgene Expression in T Lymphocytes. <i>Human Gene Therapy</i> , 2003, 14, 1155-1168.	1.4	171
164	Inhibition of Tumor Angiogenesis by Angiostatin: From Recombinant Protein to Gene Therapy. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2002, 9, 3-10.	1.7	37
165	Expression from cell type-specific enhancer-modified retroviral vectors after transduction: influence of marker gene stability. <i>Gene</i> , 2002, 283, 199-208.	1.0	11
166	Alternatively spliced forms of Ig $\lambda$ and Ig $\lambda$ <sup>2</sup> prevent B cell receptor expression on the cell surface. <i>European Journal of Immunology</i> , 2002, 32, 1530.	1.6	19
167	Encapsulated cells producing retroviral vectors for in vivo gene transfer. <i>Journal of Gene Medicine</i> , 2002, 4, 150-160.	1.4	21
168	The Isomerization Plant at Rosneft' Oil Company – Komsomol'sk Oil Refinery Open Joint-stock Company. <i>Chemistry and Technology of Fuels and Oils</i> , 2002, 38, 287-292.	0.2	0
169	Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. <i>Cancer Research</i> , 2002, 62, 6099-107.	0.4	41
170	Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. <i>Blood</i> , 2001, 98, 3607-3617.	0.6	28
171	Modulation of Moloney Leukemia Virus Long Terminal Repeat Transcriptional Activity by the Murine CD4 Silencer in Retroviral Vectors. <i>Virology</i> , 2000, 276, 83-92.	1.1	10
172	Biochemical and genetic defects underlying human congenital hypotransferrinemia. <i>The Hematology Journal</i> , 2000, 1, 390-398.	2.0	28
173	Mutator Phenotype in Human Hematopoietic Neoplasms and Its Association With Deletions Disabling DNA Repair Genes and bcl-2 Rearrangements. <i>Blood</i> , 1999, 94, 2424-2432.	0.6	29
174	Frequency of a Mutated CCR-5 Allele (Delta32) among Italian Healthy Donors and Individuals at Risk of Parenteral HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 337-344.	0.5	20
175	DNA Immunization of Mice against SIVmac239 Gag and Env Using Rev-Independent Expression Plasmids. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 83-90.	0.5	22
176	TCR Expression and Clonality Analysis in Peripheral Blood and Lymph Nodes of HIV-Infected Patients. <i>Human Immunology</i> , 1997, 57, 93-103.	1.2	13
177	Identification of a human endogenous LTR-like sequence using HIV-1 LTR specific primers. <i>Molecular and Cellular Probes</i> , 1996, 10, 443-451.	0.9	3
178	Analysis of Epstein-Barr virus (EBV) type and variant in spontaneous lymphoblastoid cells and Hu-SCID mouse tumours. <i>Molecular and Cellular Probes</i> , 1996, 10, 453-461.	0.9	7
179	The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats. <i>Seminars in Immunology</i> , 1996, 8, 249-254.	2.7	16
180	Genetic variability of the human CD4 V2 domain. <i>Immunogenetics</i> , 1996, 44, 70-72.	1.2	7

#	ARTICLE	IF	CITATIONS
181	Genetic variability of the human CD4 V2 domain. <i>Immunogenetics</i> , 1996, 44, 70-72.	1.2	0
182	A CD3+CD8+ T Cell Population Lacking CD5 Antigen Expression Is Expanded in Peripheral Blood of Human Immunodeficiency Virus-Infected Patients. <i>Clinical Immunology and Immunopathology</i> , 1995, 77, 253-261.	2.1	28
183	Dominance of a single Epstein-Barr virus strain in SCID-mouse tumors induced by injection of peripheral blood mononuclear cells from healthy human donors. <i>Virus Research</i> , 1995, 36, 215-231.	1.1	9
184	B cell activation and human immunodeficiency virus infection. V. Phenotypic and functional alterations in CD5+ and CD5? B cell subsets. <i>Journal of Clinical Immunology</i> , 1993, 13, 381-388.	2.0	25
185	Standardization of in vitro synthesis and detection of HIV-1-specific antibodies. <i>Journal of Immunological Methods</i> , 1993, 157, 105-115.	0.6	13
186	Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1